HYPOCHONDROPLASIA
Clinical trials for HYPOCHONDROPLASIA explained in plain language.
Never miss a new study
Get alerted when new HYPOCHONDROPLASIA trials appear
Sign up with your email to follow new studies for HYPOCHONDROPLASIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug may boost growth in kids with rare bone disorder
Disease control OngoingThis study tests a drug called vosoritide in 80 children aged 3 to 17 with hypochondroplasia, a condition that causes short stature. The goal is to see if it safely increases growth rate over one year compared to a placebo. Participants must have a confirmed genetic diagnosis and…
Matched conditions: HYPOCHONDROPLASIA
Phase: PHASE3 • Sponsor: BioMarin Pharmaceutical • Aim: Disease control
Last updated May 26, 2026 04:37 UTC
-
New drug shows promise for helping children with rare bone disorder grow taller
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety and effectiveness of a daily pill called infigratinib for children with hypochondroplasia, a condition that causes short stature. About 135 children who previously took part in related studies will receive the drug for up to several years.…
Matched conditions: HYPOCHONDROPLASIA
Phase: PHASE2 • Sponsor: QED Therapeutics, a BridgeBio company • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
New drug aims to boost growth in kids with rare bone disorder
Disease control ENROLLING_BY_INVITATIONThis study tests a drug called infigratinib in 24 children with hypochondroplasia, a condition that causes short stature. The goal is to see if it can safely improve growth rate. The study has two phases: first, all children get the drug, then some get a placebo to compare result…
Matched conditions: HYPOCHONDROPLASIA
Phase: PHASE2, PHASE3 • Sponsor: QED Therapeutics, a BridgeBio company • Aim: Disease control
Last updated May 15, 2026 11:54 UTC